How a Specific Eye Drop Formula Treats Glaucoma

A patent for a precise, low-concentration eye drop solution designed to lower eye pressure in patients with glaucoma or ocular hypertension.

What it covers

This patent covers a specific pharmaceutical liquid formulation used as an eye drop to treat glaucoma. The active ingredient is a chemical compound called isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate. The claims define a very narrow concentration range of this ingredient, specifically between 0.001% and 0.003% (weight/volume), while maintaining a pH balance between 4.0 and 8.0. This precise mixture is intended to be applied directly to the eye to reduce intraocular pressure.

What it doesn't cover

• —Does not cover concentrations of the active ingredient outside the 0.001% to 0.003% (w/v) range.
• —Does not cover formulations with a pH level outside the 4.0 to 8.0 range.
• —Does not cover the chemical compound itself, only this specific pharmaceutical preparation.
• —Does not cover delivery methods other than eye drops or topical instillation.

The clever bit

The invention focuses on a very specific 'sweet spot' concentration range that provides the necessary pressure-lowering effect while likely minimizing the irritation or toxicity often associated with higher doses of such compounds.

Why it matters

Glaucoma is a leading cause of blindness, and managing intraocular pressure is the primary treatment. By patenting a specific, highly diluted concentration, the assignee protects a formulation that likely balances efficacy with reduced side effects or improved stability, which is critical for daily patient compliance.

Real-world examples

• 1.Rhopressa (netarsudil) or similar Rho kinase inhibitor eye drops
• 2.Prescription glaucoma eye drop medications